Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia

Leukemia Research

Volumn 31, Issue 4, 2007, Pages 531-539

  Fiegl, Michael ^a   Juergens, Matthias ^a   Hiddemann, Wolfgang ^a   Braess, Jan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AML; Cytarabine; Cytoxicity; Interaction analysis; Proliferative activity; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LC 50; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CASPASE 3; CELL PROLIFERATION; CYTARABINE; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID; MALE; MIDDLE AGED;

EID: 33846661614     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.013     Document Type: Article

References (28)

1. Melnick A., and Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93 (1999) 3167
2. Spiekermann K., Bagrintseva K., Schwab R., et al. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 9 (2003) 2140
3. Paquette R.L., Landaw E.M., Pierre R.V., et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82 (1993) 590
4. Neubauer A., Dodge R.K., George S.L., et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83 (1994) 1603
5. Fadeel B., Orrenius S., and Zhivotovsky B. The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia 14 (2000) 1514
6. Beaupre D.M., and Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 17 (1999) 1071
7. Avalos B.R. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 88 (1996) 761
8. Okuda K., Sanghera J.S., Pelech S.L., et al. Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood 79 (1992) 2880
9. Holstein S.A., and Hohl R.J. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25 (2001) 651
10. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 (2003) 840
11. Kuroda J., Kimura S., Segawa H., et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 (2003) 2229
12. Li X., Liu L., Tupper J.C., et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277 (2002) 15309
13. Bos J.L., Verlaan-de Vries M., Jansen A.M., et al. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res 12 (1984) 9155
14. SOFTmax PRO-User Manual 2.4. Sunnyvale, California: Molecular Devices Cooperation; 1998.
15. Braess J., Fiegl M., Lorenz I., et al. Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia. Clin Cancer Res 11 (2005) 7415-7425
16. Nakao M., Janssen J.W., Seriu T., and Bartram C.R. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 14 (2000) 312
17. Kaufmann S.H., Peereboom D., Buckwalter C.A., et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88 (1996) 734
18. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5 (1979) 85
19. Kano Y., Ohnuma T., Okano T., and Holland J.F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48 (1988) 351
20. Nogawa M., Yuasa T., Kimura S., et al. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15 (2005) 1
21. Kimura S., Kuroda J., Segawa H., et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 79 (2004) 37
22. Braess J., Jahns-Streubel G., Schoch C., et al. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 113 (2001) 975
23. Ohtsuka Y., Manabe A., Kawasaki H., et al. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood (2005)
24. Benford H.L., McGowan N.W., Helfrich M.H., et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465
25. Broker L.E., Kruyt F.A., and Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 11 (2005) 3155
26. Braess J., Voss S., Jahns-Streubel G., et al. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 110 (2000) 170
27. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 (2002) 1228
28. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095